![Figure 2. In vitro effects of alphastatin. (A) HuDMEC migration across a collagen-coated filter in response to medium alone (control) or medium containing 10 ng/mL VEGF or bFGF. (B) Tubule formation by HuDMECs on GF-reduced Matrigel in response to medium alone (control) or medium containing 10 ng/mL VEGF or bFGF, and (D) HuDMEC proliferation over a 48-hour period. (C) Tubule formation by HuDMECs exposed to either alphastatin (1000 nM) for 2 hours prior to the assay and then washed and added to the assay in the absence of alphastatin (but in the presence or absence of bFGF [10 ng/mL] or VEGF [10 ng/mL]) or HuDMECs exposed to alphastatin (1000 nM) during the assay alone (in the presence or absence of bFGF [10 ng/mL] or VEGF [10 ng/mL]). All data shown are means ± SEM. *P < .03 compared with respective “no alphastatin” groups.](https://ash.silverchair-cdn.com/ash/content_public/journal/blood/103/2/10.1182_blood-2003-07-2192/6/h80245542002.jpeg?Expires=1735563143&Signature=rUkGA~LFZMLfcPY24701nSlFrIG3MiiOPNYbalDS~Oq7HAklUYLSpksEVuzVIHKP3mTOJYNi5Kz74vcDY161KUt8QRW7XOIzae5xqlvjO6GXxmthudh3km7YN~Bu0fpl5gNquCAVZGYeGuENtrEytm3Q5wNezh2Rok5cChL7ZAJUaT3eG6VvMPLbdEfVh7YfmcWosfXJftVBMqBC3h0KhcdMJT2ZV-aSUV-4HJcWoBeDnKCnPm~EP9-IB6sop8I3l1~5AkXrihk3sWU7jBgkmOQpauLongTyGp10W0ef66BiN1HcTQUPfMflCDowI2427bWoYu7fC5cKnProuvyiRQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
In vitro effects of alphastatin. (A) HuDMEC migration across a collagen-coated filter in response to medium alone (control) or medium containing 10 ng/mL VEGF or bFGF. (B) Tubule formation by HuDMECs on GF-reduced Matrigel in response to medium alone (control) or medium containing 10 ng/mL VEGF or bFGF, and (D) HuDMEC proliferation over a 48-hour period. (C) Tubule formation by HuDMECs exposed to either alphastatin (1000 nM) for 2 hours prior to the assay and then washed and added to the assay in the absence of alphastatin (but in the presence or absence of bFGF [10 ng/mL] or VEGF [10 ng/mL]) or HuDMECs exposed to alphastatin (1000 nM) during the assay alone (in the presence or absence of bFGF [10 ng/mL] or VEGF [10 ng/mL]). All data shown are means ± SEM. *P < .03 compared with respective “no alphastatin” groups.
